LYS228

DRUG2 trials

Sponsors

Novartis Pharmaceuticals

Conditions

Complicated Urinary Tract InfectionsIntra-abdominal Infections

Phase 2

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)

TerminatedNCT03354754

Novartis PharmaceuticalsIntra-abdominal Infections

Start: 2018-05-15End: 2018-09-24Updated: 2021-10-11

LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Urinary Tract Infection (cUTI)

WithdrawnNCT03377426

Novartis PharmaceuticalsComplicated Urinary Tract Infections

Start: 2018-10-19End: 2019-10-28Updated: 2018-10-26

Related Papers

Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing <i>In Vitro</i> Susceptibility in Escherichia coli and Klebsiella pneumoniae.

2018-09-2427 citations